Skip to main content
Andrew Karaba, MD, Infectious Disease, Baltimore, MD

Andrew Hoover Karaba MD PhD

Transplant/Immunocompromised States


Assistant Professor

Join to View Full Profile
  • 1800 Orleans StreetBaltimore, MD 21287

  • Phone+1 410-955-5000

  • Fax+1 410-955-5001

Dr. Karaba is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Andrew Karaba is an infectious disease specialist based in Baltimore, MD, with subspecialties in transplant and oncology infectious diseases. He graduated from Northwestern University The Feinberg School of Medicine in 2015 and completed his residency and fellowship at Johns Hopkins University. Dr. Karaba is currently an Assistant Professor at Johns Hopkins University School of Medicine. His research expertise includes virology, and immunology. He has published research on the immune responses to HSV, CMV, COVID-19 and RSV.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Infectious Disease, 2017 - 2020
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 2015 - 2017
  • Northwestern University The Feinberg School of Medicine
    Northwestern University The Feinberg School of MedicineClass of 2015

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2018 - 2026
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Infectious Disease
    American Board of Internal Medicine Infectious Disease

Publications & Presentations

PubMed

Press Mentions

  • Immunocompromised Have Heterogeneous Antibody Response to RSV Vaccines
    Immunocompromised Have Heterogeneous Antibody Response to RSV VaccinesJanuary 8th, 2025
  • Study: RSV Vaccine May Be More Effective at Protecting Healthier Older Adults
    Study: RSV Vaccine May Be More Effective at Protecting Healthier Older AdultsJanuary 2nd, 2025
  • Immunocompromised Adults Present Weaker Response to RSV Vaccines
    Immunocompromised Adults Present Weaker Response to RSV VaccinesDecember 31st, 2024
  • Join now to see all

Grant Support

  • Modulation of Herpes Simplex Virus Pathogenesis by Leucine Rich Repeat Kinase 2JOHNS HOPKINS UNIVERSITY2021–2026
  • Modulation of Herpes Simplex Virus Pathogenesis by Leucine Rich Repeat Kinase 2JOHNS HOPKINS UNIVERSITY2021–2026

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: